Manage Your Liver
Q:

World Hepatitis Day 2016 - Focus on long term protection after treatment to achieve a 65% reduction in deaths

World Hepatitis Day 2016 - Focus on long term protection after treatment to achieve a 65% reduction in deaths
A:

The World Health Organization’s strategy on viral hepatitis in 2015 estimated that there would be 1.4 million deaths from hepatitis-related diseases in 2016. The mortality rate is very high and the number of deaths is far greater than the sum of deaths from Malaria and HIV [1]. Therefore, one of the main targets of World Hepatitis Day 2016 is to reduce hepatitis-related deaths by 65% by 2030, through improving vaccination, preventing early-life infection and providing universal access to treatment.

 

A 65% reduction is not an easy target and in order to achieve this target by 2030, there is a key factor that cannot be neglected but was not mentioned above: post-treatment recovery and protection.

 

A recent study stated that even after successful eradication of hepatitis C virus and achieving sustained virologic response (SVR), the risk of hepatocellular carcinoma (HCC) or liver cancer remains [2]. Another research conducted by the University of Barcelona pointed out that after receiving treatment, some hepatitis C patients developed HCC and the progression was very fast. Research suspected that this was due to the immune system, and suggested that hepatitis C patients monitor their condition closely after treatment, especially those who had HCC or liver fibrosis previously[3].

 

These results show that the risk of serious liver diseases remains even after successful treatment. In addition, after eliminating the virus, the liver needs to rely on its self-repair ability to produce new liver cells so that normal liver function can resume. Therefore, enhancing liver recovery and protection is an integral part that should be added to the strategy. In order to reduce the number of deaths caused by hepatitis-related diseases by 65% effectively, post-treatment liver protection measures must be improved to ensure the liver’s longevity and lower the risk of death.

 

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Tags:
world hepatitis Dat 2016long term protectionafter careliver protectionYHK
Related Questions
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
NASH (Nonalcoholic Steatohepatitis) is closely linked with NAFLD (Non-alcoholic fatty liver disease). Both of these liver diseases are common, and are often known as silent liver killers. NASH resembles alcoholic liver disease, but occurs in people who drink little or no alcohol at all. The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is
Hit Questions
A:
Research and developing our products has always been a big part of our work. Kyotsujigyo has worked with a number of well established organisations and universities in the past, including the University of Sao Paulo, GAIA Age-Management Foundation, The University of Western Ontario, University of Virginia, Yanaihara Research Institute,  Harada Hospital (Japan) and others.    In 2016 Kyotsujigyo has corporate with the National Key Research Institute in Hong K
A:
NASH is inflammation in the liver developed from accumulated fat in the organ, also known as fatty liver. NASH damages liver cells and liver function, which results in elevated ALT liver enzyme level.    As there are no approved treatments for NASH, the standard recommendation for patients is to lose weight only. However this doesn’t work for everyone so if you are struggling to find a way to stop NASH, please read on.   Wha
A:
In 2010, some 4.7 million people aged 65 years or older lived with Alzheimer's disease in the US.   Alzheimer’s is a common brain disease that causes progressive brain cell death that happens over a course of time. It will also cause a shrink in brain size as the tissue has progressively fewer nerve cells and connections. Alzheimer’s is thought to be caused by Protein Plaques building up in the brain cells, these Plaques are found between the dying cel
A:
There are between 10 to 15 million patients in the U.S. with NASH, and among these patients, one-fifth to one-fourth are at risk for cirrhosis or chronic liver damage.   The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1] Ther
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Have
Questions?
Sumbit your question
to us for profeessional answers!
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Looking for help? Ask our customer support team!
Contact Us